Alemtuzumab induction in non-hepatitis C positive liver transplant recipients
Authors:
Open Access
- 31 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 17 (1) , 32-37
Abstract
Limited data exist for the use of alemtuzumab (AL) induction in liver transplantation (LT) recipients. We compared the outcomes of hepatitis C virus-negative LT recipients who received AL induction followed by tacrolimus and mycophenolate mofetil without steroids to cohort who received no AL induction, tacrolimus, and a steroid taper. Fifty-five AL-induced recipients were compared to 85 non-AL-induced recipients with similar characteristics. Two-year patient survival (80% versus 88.2%, P = 0.0665) and graft survival (76.4% versus 82.4%, P = 0.1792) were not significantly different between the AL and non-AL groups, respectively. Other outcomes, including acute rejection (20% versus 30.3%), renal dysfunction (creatinine levels: 1.3 ±0.3 versus 1.4 ± 0.6 mg/dL), and immunosuppressant monotherapy (29.1% versus 44.3%), were not significantly different between the AL and non-AL groups, respectively (P > 0.05). The number of rejection episodes (12 versus 42, P = 0.02) and the number of patients with new-onset hypertension (3 versus 15, P = 0.03) were lower in the AL group, although the incidence of all posttransplant infections was higher with AL (63.6% versus 44.3%, P = 0.03), primarily because of an increase in viral infections. In conclusion, a steroid-free AL induction regimen was associated with less hypertension and rejection but with more infectious complications; thus, the overall benefit of AL induction in LT recipients is called into question. Liver Transpl 17:32-37, 2011. © 2011 AASLD.Keywords
This publication has 14 references indexed in Scilit:
- Alemtuzumab and liver transplantation: a reviewCurrent Opinion in Organ Transplantation, 2009
- Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumabClinical Transplantation, 2008
- Cryptococcosis in liver and kidney transplant recipients receiving anti‐thymocyte globulin or alemtuzumabTransplant Infectious Disease, 2007
- Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 AntibodyClinical Infectious Diseases, 2007
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- The Impact of Campath 1H Induction in Adult Liver AllotransplantationTransplantation Proceedings, 2005
- Prope tolerance—the future of organ transplantation from the laboratory to the clinicInternational Immunopharmacology, 2005
- Preliminary experience with campath 1H (C1H) in intestinal and liver transplantationTransplantation, 2003
- CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1999
- Banff Schema for Grading Liver Allograft Rejection: An International Consensus DocumentHepatology, 1997